Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights

Fig. 1

8 out of 16 drugs were able to reduce cell viability in GCT cell lines. A Table of the initial 16 drugs tested in 3 GCT cell lines. The color/symbol code is based on the EC50 after 48 h of treatment as determined by XTT assay. See also Additional file 2: Fig. S2 (n = 4). B List of the mean EC50 values per GCT entity, as well as fibroblasts and Sertoli cells, after 48 h. See also data in Additional file 3: Fig. S3. For single values, see Additional file 4: Fig. S4A. C Gene expression profiles of the TCGA 'Testicular Germ Cell Tumors' cohort for each target gene. D Expression analysis of TCGA data for each target gene in the urological tumor entities UC, PCa and RCC. E Mean EC50 values of three cell lines from UC, PCa and RCC. For raw data, see Additional file 4: Fig. S4C–E. For single values, see Additional file 4: Fig. S4F (n = 4). F, G Flow cytometric analysis of apoptosis (F) and cell cycle (G) after 16 h. Only changes over 5% compared to solvent control were considered significant. See also Additional file 5: Fig. S5. EC50: half-maximal effective concentration where the cell viability has 50% compared to the solvent control; SE, seminoma; EC, embryonal carcinoma; YST, yolk-sac tumor; CC, choriocarcinoma; SC, Sertoli cells; -R, cisplatin-resistant subclone; UC, urothelial carcinoma; PCa, prostate cancer; RCC, renal cell carcinoma

Back to article page